Metabolic risks of hyperuricemia

Hyperuricemia (HU), traditionally considered as an important risk factor and therapeutic target for patients with gout, currently draws attention of many researchers from the perspective of its contribution to the pathogenesis of metabolic syndrome and metabolic syndrome-associated diseases. The study aimed to determine the frequency of detection of HU and its conjugation with burden of metabolic comorbidities in outpatients. HU was detected in 253 (27.1%) of 933 people referred to the determination of the uric acid (UA) level. The investigators took into account the presence of established diagnosis of gout, cardiovascular system diseases associated with metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease (CKD) and urolithiasis, and nonalcoholic fatty liver disease. The study showed that patients with HU had four times higher metabolic comorbidity level than individuals with normal UA levels. Not only gout (6.25 times), but also urolithiasis with CKD (2.2 times) and cardiovascular disease (CVD) (1.9 times) were more common in people with elevated UA levels. Among patients with HU, women were 2.2 times more likely to have type 2 diabetes than men. Patients with type 2 diabetes and CVD, especially women, need to correct HU to reduce the risk of progression of metabolic disorders. The article presents a brief overview of modern drugs for the management of GU.

hyperuricemia, gout, metabolic syndrome-associated cardiovascular diseases, diabetes mellitus, allopurinol, febuxostat

1. Li Q., Li X., Wang J., Liu H. et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019;9(8):1-13. doi: 10.1136/bmjopen-2018-026677.

2. Richette P., Doherty M., Pascual E., Barskova V. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42. doi: 10.1136/annrheumdis-2016-209707 .

3. Shalnova S.A., Deev A.D., Artamonov G.V., Duplyakov D.V. et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Ratsional’naya farmakoterapiya v kardiologii = Ration Pharmacotherapy Cardioly. 2014;10(1):153-159. (In Russ.) Available at: https://elibrary.ru/download/elibrary_21503850_37026040.pdf.

4. Zhu Y., Bhavik J., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US General population: the National Health and nutrition examination survey 2007-2008. Arthritis Rheumatism. 2011;63(10):3136-3141. doi: 10.1002/art.30520.

5. Abdurhman S.A.-A. Hyperuricemia in Saudi Aradia. Rheumatology International. 2001;20(2):61-64. https://doi.org/10.1007/ s002960000076.

6. Chu N.F., Wang D.J., Liou S.H., Shieh S.M. Relationship between hyperuricemia and other cardiovascular risk factors among adults men in Taivan. Eur J Epidemol 2000;16(1):1317. doi: 10.1023/A:1007654507054.

7. Myasoedova S.E. New Possibilities of Hypouricemic Therapy for Gout. Trudnyy patsient = The difficult patient. 2018;(3):28-31. (In Russ.) Available at: https://cyberleninka.ru/ article/v/novye-vozmozhnosti-uratsnizhayuschey-terapii-pri-podagre.

8. Galushko E.A., Nasonov E.L. Prevalence of rheumatic diseases in Russia. Al’manakh Klinicheskoy Meditsiny = Almanac of Clinical Medicine. 2018;46(1):32–9. (In Russ.) doi: 10.18786/2072-0505-2018-46-1-32-39.

9. Shirokova I., Progerina Yu. A new step in treatment «Disease of the kings». Remedium. 2018;(3):33-38. (In Russ.) Available at: http:// remedium-journal.ru/upload/iblock/57a/ RM_03_2018_07.pdf.

10. Lima W.G., Martins-Santos M.E., Chaves V.E. Uric acid as a modulator of glucose and lipid metabolism. Biochimie. 2015;116:17-23. doi: 10.1016/j.biochi.2015.06.025.

11. Ilyina A.E., Barskova V.G., Nasonov E.L. Asymptomatic hyperuricemia - benefit or harm? RMZH = RMJ. 2008;16(24):1619-1624. (In Russ.) Avaliable at: https://www.rmj.ru/articles/revmatologiya/Bessimptomnaya_giperurikemiya__polyza_ili_vred/.

12. Rho Y.H., Choi S.J., Lee Y.H. et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. Journal of Korean Medical Science. 2005;20(6):1029-33. Avaliable at: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2779304/pdf/jkms-20-1029.pdf.

13. Green D., Foiles N., Chan C. еt аl. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study. Atherosclerosis. 2009;202(2):623–631. Avaliable at: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2662501/pdf/nihms94662.pdf.

14. Nielsen S.M., Bartels E.M., Henriksen M. et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Annals of the Rheumatic Diseases. 2017;76(11):1870–1882. doi: 10.1136/annrheumdis-2017-211472.

15. Yakupova S.P. Gout. New opportunities of diagnosis and treatment. Terapevticheskiy arkhiv = The Therapeutic Archive. 2018;90(5):88-92. (In Russ.) doi: 10.26442/terarkh201890588-92.

16. Baker J.F., Krishnan E., Chen L., Schumacher H.R. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? American Journal of Medicine. 2005;118(8):816–826. doi: 10.1016/j. amjmed.2005.03.043.

17. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford) 2010;49(7):1229– 1238. doi: 10.1093/rheumatology/keq037 .

18. Gilyarevsky S.R., Kuzmina I.M., Kelekhsayev Kh.R., Sklifosovsky N.V. Uric acid and cardiovascular diseases: a new C-reactive protein? Sistemnye gipertenzii = Systemic hypertension. 2011;(3):44-47 (In Russ.) Available at: http:// www.gipertonik.ru/files/journals/SG3(2011).pdf.

19. Verdecchia P., Schillaci G., Reboldi G. et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000;36:1072– 1078. Available at: https://www.ahajour nals.org/ doi/pdf/10.1161/01.HYP.36.6.1072.

20. Alderman M.H., Cohen H., Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. Journal of Hypertension. 1998;16(6):761–769. doi: 10.1097/00004872-199816060-00007 .

21. Fang J., Alderman M.H. Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992. JAMA. 2000;283(18):2404–2410. doi: 10.1001/ jama.283.18.2404.

22. Sautin Y.Y., Johnson R.J. Uric acid: the oxidantantioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):608–619. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2895915/pdf/nihms212414.pdf.

23. Leyva F., Anker S., Swan J.W., Godsland I.F. et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure, European Heart Journal. 1997;18(5):858–865. doi: 10.1093/oxfordjournals.eurheartj.a015352.

24. Coutinho T.de A., Turner S.T., Peyser P.A. et al. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. American Journal of Hypertension. 2007;20(1):83–89. doi: 10.1016/j.amjhyper.2006.06.015.

25. Strasak A., Ruttmann E., Brant L. et al. Ulmer H. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clinical Chemistry. 2008;54(2):273– 84. doi: 10.1373/clinchem.2007.094425.

26. Mazzali M., Kanbay M., Segal M.S. et al. Uric acid and hypertension: cause or effect? Current Rheumatology Reports. 2010;12(2):108– 17. doi: 10.1007/s11926-010-0094-1.

27. Enomoto A., Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clinical and Experimental Nephrology. 2005;9(3):195–205. doi: 10.1007/s10157-0050368-5.

28. Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk. N. Engl. J. Med. 2008;359(17):1811–1121. Available at: https:// www.ncbi.nlm.nih.gov/pmc/articles/ PMC2684330/pdf/nihms109052.pdf.

29. Woyesa S.B., Hirigo A.T., Wube T.B. Hyperuricemia and metabolic syndrome in type 2 diabetes mellitus patients at Hawassa university comprehensive specialized hospital, South West Ethiopia. BMC Endocr Disord. 2017;17(1):76. doi: 10.1186/s12902-017-0226-y.

30. Han Y., Zhang M., Lu J. et al. Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes. Scientific Reports. 2017;7(1):3802. doi: 10.1038/ s41598-017-04036-6.

31. Widecka K., Szymański F.M., Filipiak K.J. еt аl. Hyperuricemia and its treatment in patients with a high cardiovascular risk – experts opinion. Arterial Hypertens. 2017;21(1):10–17. Available at: https://pdfs.semanticscholar.org/ b3fb/11e1b27cfa0c78c3c725cff4d68d1673b2 2e.pdf.

32. Luk A.J., Levin G.P., Moore E.E. еt аl. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford). 2009;48(7):804–806. Available at: https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4481712/pdf/kep069.pdf.

33. Agarwal V., Hans N., Messerli F.H. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. Journal of Clinical Hypertension. (Greenwich). 2013;15(6):435–442. Available at: https://onlinelibrary.wiley.com/ doi/epdf/10.1111/j.1751-7176.2012.00701.x.

34. Keenan R.T. Limitation of the current standarts of care for treating gout and crystal deposition in the primary care setting: a rewiev. Clinical Therapeutics. 2017;39(2):430−440. doi: 10.1016/j.clinthera.2016.12.011.

35. Barskova V.G., Ilyinykh E.V., Nasonov E.L. Febuxostat is a novel drug in therapy for gout. Nauchno­prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;49(2):52-58. (In Russ.) doi: 10.14412/1995-4484-2011-603.

36. Becker M.A., Schumacher H.R., Wortmann R.L. et al Febuxostat compared with allopurinol in patients with hyperuricemia and gout. The New England Journal of Medicine. 2005;353(23):2450-2461. doi: 10.1056/ NEJMoa050373.

37. Schumacher H.R., Becker M.A.,Wortmann R.L. et al. The FOCUS trial 48-month interim analysis: long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open-label extension study. Annals of the Rheumatic Diseases. 2006;65:93. Available at: https://acr.confex.com/acr/2006/ webprogram/Paper4119.html.

38. Schumacher H.R., Becker M.A., Wortmann R.L. et al. Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study. Arthritis and Rheumatism. 2008;59(11):1540-8. doi: 10.1002/art.24209.

39. White W.B., Saag K.G., Becker M.A. et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England Journal of Medicine. 2018;378(13):12001210. doi: 10.1056/NEJMoa1710895.

40. White W.B., Chohan S., Dabholkar A. et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidi- ties. American Heart Journal. 2012;164(1):14–20. doi: 10.1016/j. ahj.2012.04.011.

41. Tsurko V.V., Gromov M.A., Eliseeva M.E. Gout Therapy that Reduces Urates, Focus on Febuxostat (Based on the Materials Recommended by the European Antirheumatic League). Trudnyy patsient = The difficult patient. 2017;15(3):24-26. (In Russ.) Available at: http://t-pacient.ru/wp-content/ uploads/2017/06/3.pdf

42. Saag K.G., Whelton A., Becker M.A., MacDonald P. et al. Impact of Febuxostat on Renal Function in Gout Patients With Moderate-toSevere Renal Impairment. Arthritis and Rheumatology. 2016;68(8):2035-2043. doi: 10.1002/art.39654.

43. Yamanaka H., Tamaki S., Ide Y., et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Annals of the Rheumatic Diseases. 2018;77(2):270–276. doi: 10.1136/ annrheumdis-2017-211574.

44. Dalbeth N., Saag K.G., Palmer W.E. et al. Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. Arthritis and Rheumatology. 2017;69(12):2386– 2395. doi: 10.1002/art.40233.

45. Hosoya T., Sasaki T., Ohashi T. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. Clinical Rheumatology. 2017;36(3):649656. doi: 10.1007/s10067-016-3474-8.

46. Poiley J., Steinberg A.S., Choi Y.J., Davis C.S. et al. A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout. Arthritis and Rheumatology. 2016;68(8):2027-2034. doi: 10.1002/art.39684.

47. Steinberg A.S., Vince B.D., Choi Y.J., Martin R.L. et al. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout. The Journal of Rheumatology. 2017;44(3):374379. doi: 10.3899/jrheum.161062.

48. Bardin T., Keenan R.T., Khanna P.P., Kopicko J. et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases. 2017;76(5):811-820. doi: 10.1136/annrheumdis-2016-209213.

49. Saag K.G., Fitz-Patrick D., Kopicko J., Fung M. et al. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis and Rheumatoly. 2017;69(1):203-212. doi: 10.1002/art.39840.

50. Dalbeth N., Jones G., Terkeltaub R. et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis and Rheumatoly. 2017;69(9):1903–1913. doi: 10.1002/art.40159.